Pulse Biosciences, Inc. (PLSE)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Pulse Biosciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Pulse Biosciences, Inc. (PLSE) has returned 57.25% so far this year and 34.18% over the past 12 months.

Based on dividend-adjusted daily data since May 18, 2016, PLSE's average daily return is +0.23%, while the average monthly return is +4.64%. At this rate, your investment would double in approximately 1.3 years.

Historically, 50% of months were positive and 50% were negative. The best month was Feb 2017 with a return of +105.2%, while the worst month was Feb 2022 at -58.2%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 10 months.

On a daily basis, PLSE closed higher 48% of trading days. The best single day was Feb 6, 2026 with a return of +51.6%, while the worst single day was Feb 8, 2022 at -34.4%.

Pulse Biosciences, Inc. has an annualized alpha of 51.08%, beta of 1.20, and R² of 0.06 versus S&P 500 Index. Calculated based on daily prices since May 19, 2016.

• This stock captured 191.30% of S&P 500 Index gains and 154.37% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.06 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PLSE ranks 60 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Pulse Biosciences, Inc. (PLSE) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Pulse Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Pulse Biosciences, Inc. was 97.22%, occurring on Aug 30, 2022. The portfolio has not yet recovered.

The current Pulse Biosciences, Inc. drawdown is 51.23%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Pulse Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Pulse Biosciences, Inc. is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.